Skip to content
Calculator
Compare

KPV vs BPC-157

Last updated: October 3, 2026 · 5 min read · By the Grey Peptides Editorial Board

Close-up of a patient consulting a doctor with a clipboard in a medical setting
Photo by Thirdman on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Both are sold for gut inflammation and both were voted through by FDA's compounding advisory committee in July 2026, a recommendation FDA has not yet acted on.
  • KPV has never been tested in people. Its evidence is mouse colitis models and cell studies. BPC-157 has rodent gut studies and two tiny human reports, neither in gut disease.
  • Inflammatory bowel disease has many approved treatments with trial evidence; neither peptide is one of them.

Side by side

KPV Low and BPC-157 Low are both graded low. The table is read from our encyclopedia entries.

FieldKPVBPC-157
Encyclopedia entryKPV Full entryBPC-157 Full entry
Molecule classPeptidePeptide
CategoryHealing & RecoveryHealing & Recovery
FDA statusResearch ChemicalResearch Chemical
Approved elsewhereNone recordedNone recorded
Evidence gradeLowLow
Half-lifeNot measuredShort systemic half-life (minutes) but prolonged tissue effect
FormulaC16H30N4O4C62H98N16O22
Molecular weight342.4 g/mol1,419.5 g/mol
WADA 2026Prohibited (S0 catch-all)Prohibited at all times (S0)
WADA 2027Prohibited (S0 catch-all)Prohibited at all times (S0)
In one lineA tripeptide from the tail of α-MSH: anti-inflammatory in mouse colitis and cell studies, never tested in people, and recommended for compounding by FDA's advisers in July 2026.A synthetic pentadecapeptide from gastric protein, widely studied in animal models for tendon, ligament, and gastrointestinal healing.
MechanismEnters gut epithelial and immune cells through the di/tripeptide transporter PepT1, which inflammation induces in the colon, and suppresses NF-κB and MAP kinase signalling; in airway cells it enters the nucleus and appears to block NF-κB p65's importin binding site. Its anti-inflammatory effect persisted in mice without functional MC1R, was not blocked by an MC3/4 antagonist and did not raise cAMP. All evidence is from cells and rodents.BPC-157 promotes angiogenesis via upregulation of VEGFR2 expression and activation of the Egr-1/NAB2 pathway, modulates nitric oxide signaling, and interacts with the dopaminergic and serotonergic systems in animal models. Effects are observed on tendon, ligament, muscle, bone, gastrointestinal tissue, and the blood-brain barrier. Despite extensive preclinical literature, no peer-reviewed human efficacy trials have been published as of 2026.
Sources in the entry1412
Study cards1411
Dosage pageDosage pageDosage page

What each is

KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with anti-inflammatory effects. The tripeptide was first studied for reducing fever in rabbits, where it was less potent than alpha-MSH 1, and later for inflammation in the gut 2.

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. Its early studies were of stomach ulcers in rats, in which intramuscular and oral doses reduced ulcer area 3, and its developers have since reported healing effects across many organs in animals 4.

KPV's evidence

In 2008, researchers showed that nanomolar amounts of KPV blocked NF-kappaB and MAP kinase signalling, two central inflammatory pathways, in human gut epithelial cells and T cells, that it entered cells through the transporter PepT1, and that KPV in drinking water reduced the severity of chemically induced colitis in mice 2. A second group found that KPV-treated mice recovered faster in two different colitis models 5. Later work loaded KPV into nanoparticles and hydrogels to target the inflamed colon in mice and rats 6. Every study is in cells or animals; no published study has given KPV to a person.

One study complicates the picture: mice engineered to make more of the PepT1 transporter in the gut developed more colitis-associated tumours, and KPV prevented tumours in normal mice but had different effects depending on PepT1 7. The implications for people are unknown.

BPC-157's evidence

BPC-157's gut evidence is also animal. Beyond the ulcer models, rats with obstructed bile ducts given BPC-157 had less jaundice, fluid build-up and liver damage 8. Its human data are a two-person intravenous safety pilot 9 and an uncontrolled knee chart review 10; neither involved the gut. No trial has tested BPC-157 in inflammatory bowel disease or any other gut condition in people.

What the July 2026 vote means

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend both KPV and BPC-157 for the list of substances pharmacies may use in compounding, against the advice of FDA's own reviewers 11. That is advice, not approval. As of October 3, 2026, FDA had not acted, so neither can yet be lawfully compounded, and even if they are listed, compounding is not a finding that a substance is safe or effective. Our July 2026 PCAC page sets out every vote.

What people with gut disease use instead

Ulcerative colitis and Crohn's disease have a long list of approved treatments tested in large trials, from aminosalicylates and steroids to immune-modulating drugs and biologics, and newer oral drugs. A person with inflammatory bowel disease who replaces or delays effective treatment with an untested peptide risks flares and complications. Anyone considering KPV or BPC-157 should discuss it with their gastroenterologist, and tell them about anything already taken.

Sport status

Both are prohibited at all times under the WADA Code: BPC-157 is named under S0, non-approved substances, and KPV falls under the same catch-all for substances with no approval for human use 12.

How the differences add up (as of October 3, 2026)

KPV has a coherent mechanism and positive mouse colitis studies but no human data at all. BPC-157 has a larger animal literature, two small human reports outside the gut, and the same lack of human gut trials. Both are investigational in every sense that matters for a patient. Our guide to reading a study explains why mouse colitis results so often fail to translate.

Frequently asked questions

Is KPV or BPC-157 better for gut health?

Neither has been tested in people with gut disease. KPV has mouse colitis studies; BPC-157 has rat ulcer and liver studies.

Has KPV been tested in humans?

No. Every published KPV study is in cells or animals.

Are KPV and BPC-157 legal to compound?

Not yet. FDA's advisory committee recommended both in July 2026, but FDA had not acted as of October 3, 2026, so pharmacies could not lawfully compound them.

Sources

  1. Richards, D. B., et al. (1984). Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides, 5(4), 815-7. PMID: 6333677
  2. Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-78. PMID: 18061177
  3. Xue, X. C., et al. (2004). Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol, 10(7), 1032-6. PMID: 15052688
  4. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24(18), 1972-1989. PMID: 29998800
  5. Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14(3), 324-31. PMID: 18092346
  6. Xiao, B., et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther, 25(7), 1628-1640. PMID: 28143741
  7. Viennois, E., et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol, 2(3), 340-357. PMID: 27458604
  8. Sever, A. Z., et al. (2019). Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. Eur J Pharmacol, 847, 130-142. PMID: 30690000
  9. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  10. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  11. U.S. Food and Drug Administration. July 23, 2026 Pharmacy Compounding Advisory Committee votes on BPC-157 and KPV (8 yes, 6 no, 1 abstain each). Re-read October 3, 2026.
  12. Grey Peptides dataset records for KPV and BPC-157 (status, WADA status and sources as recorded on each entry); read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead